{
    "clinical_study": {
        "@rank": "138012", 
        "arm_group": [
            {
                "arm_group_label": "IncobotulinumtoxinA", 
                "arm_group_type": "Experimental", 
                "description": "20U injection equal aliquots of 0.1 mL (4U) to 5 injection points."
            }, 
            {
                "arm_group_label": "Toxin II", 
                "arm_group_type": "Active Comparator", 
                "description": "20U/injection: equal aliquots of 0.1 mL (4U) to 5 injection points"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to show that two FDA-approved Botulinum toxin drugs called\n      Xeomin\u00ae and Toxin II can reduce the severity of vertical lines (wrinkles) that appear\n      between the eyebrows (called glabellar frown lines)."
        }, 
        "brief_title": "The Treatment of Glabellar Frown Lines", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Glabellar Frown Lines", 
        "detailed_description": {
            "textblock": "This is a prospective, multicenter, randomized, double-blind, parallel group clinical study\n      to investigate the equivalence of incobotulinumtoxinA (Xeomin\u00ae) to Toxin II in the treatment\n      of Glabellar Frown Lines."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Outpatient females 18 to 50 years of age\n\n          -  Moderate to severe glabellar frown lines\n\n        Exclusion Criteria:\n\n          -  Glabellar Frown Lines at rest rating 3 on the 4-point Facial Wrinkle Scale\n\n          -  Previous treatment with Botulinum toxin\n\n          -  Previous treatment with biodegradable fillers in glabellar area within last 12 months\n\n          -  Any severe or uncontrolled systemic disease, malignant tumor, or medical history of\n             HIV infection\n\n          -  Known hypersensitivity to incobotulinumtoxinA or Toxin II or to any of their\n             excipients\n\n          -  Intake of any of the forbidden concomitant medication or other agents that might\n             interfere with neuromuscular function or might interfere with the action of Botulinum\n             toxin type within 14 days prior to injection"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096081", 
            "org_study_id": "MUS 60201_4096_1"
        }, 
        "intervention": [
            {
                "arm_group_label": "IncobotulinumtoxinA", 
                "description": "20U/injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection", 
                "intervention_name": "IncobotulinumtoxinA", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Xeomin\u00ae", 
                    "NT201", 
                    "Botulinum toxin type A [150 kDa], free from complexing proteins"
                ]
            }, 
            {
                "arm_group_label": "Toxin II", 
                "description": "20U/injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection", 
                "intervention_name": "Toxin II", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Glabellar Frown Lines", 
            "Frown Lines", 
            "Facial Wrinkles"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coral Gables", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metairie", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chestnut Hill", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Merz Pharmaceuticals, LLC", 
            "last_name": "Medical Expert", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response defined as \u2265 1 point improvement from baseline (prior to treatment) on the Facial Wrinkle Scale at maximum frown as rated by an independent masked panel of physicians specifically qualified to assess study photographs using subject photographs at 1 month from treatment.", 
            "measure": "Primary Efficacy", 
            "safety_issue": "No", 
            "time_frame": "1 Month from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096081"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response defined as \u2265 1 point improvement from baseline on the Facial Wrinkle Scale (0=None to 3=severe) at maximum frown as rated by an independent masked panel of physicians specifically qualified to assess study photographs using subject photographs at 2, 3, and 4 months from treatment.", 
                "measure": "Response at maximum frown rated by independent rater", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 months from baseline"
            }, 
            {
                "description": "Response defined as \u22651 point improvement from baseline on the Facial Wrinkle Scale (0=None to 3=severe) at maximum frown as rated by the treating physicians using subject photographs at 1, 2, 3, and 4 months from treatment.", 
                "measure": "Response at maximum frown rated by treating physician", 
                "safety_issue": "No", 
                "time_frame": "4 months from baseline"
            }, 
            {
                "description": "Assessment of subject treatment satisfaction thru subject questionnaire and diary at 1, 2, 3, and 4 months from treatment.", 
                "measure": "Subject satisfaction", 
                "safety_issue": "No", 
                "time_frame": "4 months from baseline"
            }, 
            {
                "description": "Assessment of subject perception of date of treatment onset and peak effect using a take-home diary", 
                "measure": "Subject perception of treatment onset and peak effect", 
                "safety_issue": "No", 
                "time_frame": "4 months from baseline"
            }
        ], 
        "source": "Merz Pharmaceuticals, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merz Pharmaceuticals, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}